Aligos Therapeutics Inc【ALGS】株式ニュース

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Aligos Therapeutics Presents Positive Data at the EASL Congress 2026

Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the...

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a...

Form 8-K - Current report

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS...

Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026

SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS...

Form 8-K - Current report

Aligos Therapeutics Jumps on China Licensing Agreement

Aligos Therapeutics Inc. (NASDAQ:ALGS) shares surged 20% on Thursday after the company announced an exclusive licensing deal with Xiamen Amoytop...

Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

Aligos to receive an upfront payment of $25M USDUp to $420M USD in clinical, regulatory, and sales milestones...

iHub News 2月前

Aligos Therapeutics Jumps on China Licensing AgreementApril 16, 2026 10:22 AM
IH Market News
Aligos Therapeutics Inc. (NASDAQ:ALGS) shares surged 20% on Thursday after the company announced an exclusive licensing deal with Xiamen Amoytop Biotech Co., Ltd. to develop and market pevifoscorvir sodium in Greater China for the treatment of chronic hepatitis B.As part of the agreement, Aligos will receive an upfront payment of $25 million and could earn up to $420 million in milestone payments tied to clinical progress, regulatory approvals, and sales performance. The company will also receive tiered royalties in the high single-digit range on net sales across the licensed regions, which include Mainland China, Taiwan, Hong Kong, and Macau.Aligos will retain full rights to develop and commercialize pevifoscorvir sodium in markets outside Greater China, including the United States, Europe, South Korea, and Japan. It will also maintain the option to run clinical trials within Greater China, while Amoytop will be responsible for funding development activities in the region.The company said the deal is expected to extend its cash runway into the fourth quarter of 2026 under its current operating plan.Pevifoscorvir sodium is a capsid assembly modulator being developed for chronic HBV infection. The therapy is designed to inhibit viral replication, block HBV DNA integration, and reduce the cccDNA reservoir. It is currently undergoing evaluation in the Phase 2 B-SUPREME trial against tenofovir disoproxil fumarate, with a second interim analysis expected in the second half of 2026 and topline results anticipated in 2027.Greater China is home to more than 90 million people living with hepatitis B. Amoytop is a major pharmaceutical player in China, with approved treatments such as PEGBING® for chronic HBV.Completion of the transaction is subject to shareholder approval from Amoytop, which is expected within the next 30 days.Aligos Therapeutics stock price

Original: Aligos Therapeutics Jumps on China Licensing Agreement

ALGS...$9.52...🥳...Hod...Off my $6.60 Alert...

georgie18

Member Level
Re: georgie18 post# 52

Friday, November 21, 2025 4:05:38 PM

Post#
53
of 53
ALGS...$9.21...🥳... Off my $6.66 Alert... Break/Hold $9.06 and she will run...imo...we shall see...

georgie18

Member Level
Re: AugustaFriends post# 706739

Friday, November 21, 2025 12:51:16 PM

Post#
706741
of 706799
ALGS...$8.73...🥳...Off my $6.66 Alert... Break/Hold $9.06 and she will run...imo...we shall see...

georgie18

Member Level
Re: georgie18 post# 50

Wednesday, November 19, 2025 10:23:28 AM

Post#
51
of 51
ALGS...$8.59...🥳...Hod...Off my $6.66 Alert...

georgie18

Member Level
Re: georgie18 post# 400884

Tuesday, November 18, 2025 2:32:27 PM

Post#
400893
of 400916
ALGS...$8.06...🥳...Beauty move off the $6.66 Alert...

georgie18

Member Level
Re: georgie18 post# 48

Tuesday, November 18, 2025 12:12:35 PM

Post#
49
of 49
ALGS...$7.42...🥳...Off my $6.60 Alert...

georgie18

Member Level
Re: georgie18 post# 400829

Monday, November 17, 2025 10:33:21 AM

Post#
400847
of 400883
ALGS...$7.30...🥳...Off my $6.60 alert...Psar flipped Bullish...

georgie18

Member Level
Re: tw0122 post# 44

Sunday, November 16, 2025 8:34:41 AM

Post#
47
of 47
ALGS...$6.66...🥳... Bullish Engulfing Reversal Pattern... https://schrts.co/rSUukrzs ... The company has $99.10 million in cash and $6.07 million in debt, giving a net cash position of $93.03 million or $15.12 per share.

👍️0

georgie18 7月前

ALGS...$9.21...🥳... Off my $6.66 Alert... Break/Hold $9.06 and she will run...imo...we shall see...

georgie18

Member Level
Re: AugustaFriends post# 706739

Friday, November 21, 2025 12:51:16 PM

Post#
706741
of 706799
ALGS...$8.73...🥳...Off my $6.66 Alert... Break/Hold $9.06 and she will run...imo...we shall see...

georgie18

Member Level
Re: georgie18 post# 50

Wednesday, November 19, 2025 10:23:28 AM

Post#
51
of 51
ALGS...$8.59...🥳...Hod...Off my $6.66 Alert...

georgie18

Member Level
Re: georgie18 post# 400884

Tuesday, November 18, 2025 2:32:27 PM

Post#
400893
of 400916
ALGS...$8.06...🥳...Beauty move off the $6.66 Alert...

georgie18

Member Level
Re: georgie18 post# 48

Tuesday, November 18, 2025 12:12:35 PM

Post#
49
of 49
ALGS...$7.42...🥳...Off my $6.60 Alert...

georgie18

Member Level
Re: georgie18 post# 400829

Monday, November 17, 2025 10:33:21 AM

Post#
400847
of 400883
ALGS...$7.30...🥳...Off my $6.60 alert...Psar flipped Bullish...

georgie18

Member Level
Re: tw0122 post# 44

Sunday, November 16, 2025 8:34:41 AM

Post#
47
of 47
ALGS...$6.66...🥳... Bullish Engulfing Reversal Pattern... https://schrts.co/rSUukrzs ... The company has $99.10 million in cash and $6.07 million in debt, giving a net cash position of $93.03 million or $15.12 per share.

👍️0

georgie18 7月前

ALGS...$8.73...🥳...Off my $6.66 Alert... Break/Hold $9.06 and she will run...imo...we shall see...

georgie18

Member Level
Re: georgie18 post# 50

Wednesday, November 19, 2025 10:23:28 AM

Post#
51
of 51
ALGS...$8.59...🥳...Hod...Off my $6.66 Alert...

georgie18

Member Level
Re: georgie18 post# 400884

Tuesday, November 18, 2025 2:32:27 PM

Post#
400893
of 400916
ALGS...$8.06...🥳...Beauty move off the $6.66 Alert...

georgie18

Member Level
Re: georgie18 post# 48

Tuesday, November 18, 2025 12:12:35 PM

Post#
49
of 49
ALGS...$7.42...🥳...Off my $6.60 Alert...

georgie18

Member Level
Re: georgie18 post# 400829

Monday, November 17, 2025 10:33:21 AM

Post#
400847
of 400883
ALGS...$7.30...🥳...Off my $6.60 alert...Psar flipped Bullish...

georgie18

Member Level
Re: tw0122 post# 44

Sunday, November 16, 2025 8:34:41 AM

Post#
47
of 47
ALGS...$6.66...🥳... Bullish Engulfing Reversal Pattern... https://schrts.co/rSUukrzs ... The company has $99.10 million in cash and $6.07 million in debt, giving a net cash position of $93.03 million or $15.12 per share.

👍️0

georgie18 7月前

ALGS...$8.59...🥳...Hod...Off my $6.66 Alert...

georgie18

Member Level
Re: georgie18 post# 400884

Tuesday, November 18, 2025 2:32:27 PM

Post#
400893
of 400916
ALGS...$8.06...🥳...Beauty move off the $6.66 Alert...

georgie18

Member Level
Re: georgie18 post# 48

Tuesday, November 18, 2025 12:12:35 PM

Post#
49
of 49
ALGS...$7.42...🥳...Off my $6.60 Alert...

georgie18

Member Level
Re: georgie18 post# 400829

Monday, November 17, 2025 10:33:21 AM

Post#
400847
of 400883
ALGS...$7.30...🥳...Off my $6.60 alert...Psar flipped Bullish...

georgie18

Member Level
Re: tw0122 post# 44

Sunday, November 16, 2025 8:34:41 AM

Post#
47
of 47
ALGS...$6.66...🥳... Bullish Engulfing Reversal Pattern... https://schrts.co/rSUukrzs ... The company has $99.10 million in cash and $6.07 million in debt, giving a net cash position of $93.03 million or $15.12 per share.

👍️0

georgie18 7月前

ALGS...$8.06...🥳...Beauty move off the $6.66 Alert...

georgie18

Member Level
Re: georgie18 post# 48

Tuesday, November 18, 2025 12:12:35 PM

Post#
49
of 49
ALGS...$7.42...🥳...Off my $6.60 Alert...

georgie18

Member Level
Re: georgie18 post# 400829

Monday, November 17, 2025 10:33:21 AM

Post#
400847
of 400883
ALGS...$7.30...🥳...Off my $6.60 alert...Psar flipped Bullish...

georgie18

Member Level
Re: tw0122 post# 44

Sunday, November 16, 2025 8:34:41 AM

Post#
47
of 47
ALGS...$6.66...🥳... Bullish Engulfing Reversal Pattern... https://schrts.co/rSUukrzs ... The company has $99.10 million in cash and $6.07 million in debt, giving a net cash position of $93.03 million or $15.12 per share.

👍️0

georgie18 7月前

ALGS...$7.42...🥳...Off my $6.60 Alert...

georgie18

Member Level
Re: georgie18 post# 400829

Monday, November 17, 2025 10:33:21 AM

Post#
400847
of 400883
ALGS...$7.30...🥳...Off my $6.60 alert...Psar flipped Bullish...

georgie18

Member Level
Re: tw0122 post# 44

Sunday, November 16, 2025 8:34:41 AM

Post#
47
of 47
ALGS...$6.66...🥳... Bullish Engulfing Reversal Pattern... https://schrts.co/rSUukrzs ... The company has $99.10 million in cash and $6.07 million in debt, giving a net cash position of $93.03 million or $15.12 per share.

👍️0

georgie18 7月前

ALGS...$7.30...🥳...Off my $6.60 alert...Psar flipped Bullish...

georgie18

Member Level
Re: tw0122 post# 44

Sunday, November 16, 2025 8:34:41 AM

Post#
47
of 47
ALGS...$6.66...🥳... Bullish Engulfing Reversal Pattern... https://schrts.co/rSUukrzs ... The company has $99.10 million in cash and $6.07 million in debt, giving a net cash position of $93.03 million or $15.12 per share.

👍️0

georgie18 7月前

ALGS...$6.66...🥳... Bullish Engulfing Reversal Pattern... https://schrts.co/rSUukrzs ... The company has $99.10 million in cash and $6.07 million in debt, giving a net cash position of $93.03 million or $15.12 per share.

anyone understand this move?
I thought they gave up on fundamentals and wanted to cater to the low float crowd hence the 1/25
founder sold similar company prior.... maybe repeat history

👍️0

tw0122 2年前

Time to cash in some free shares .$14,62 + 50%

👍️0

DewDiligence 2年前

There were no recent insider stock purchases; rather, the three insider transactions dated 9/6/24 were company grants of stock options to the CEO, CFO, and CCO (read the footnotes):

https://www.sec.gov/Archives/edgar/data/1799448/000161071724000465/xslF345X05/form4.xml (CEO)

https://www.sec.gov/Archives/edgar/data/1799448/000161071724000466/xslF345X05/form4.xml (CFO)

https://www.sec.gov/Archives/edgar/data/1799448/000161071724000464/xslF345X05/form4.xml (CSO)

👍️0

tw0122 2年前

Insider buy at $11.74 and it finally runs

ALGS 1Q24 results:

https://www.globenewswire.com/news-release/2024/05/07/2877224/0/en/Aligos-Therapeutics-Reports-Recent-Business-Progress-and-First-Quarter-2024-Financial-Results.html

Cash at 3/31/24 was $112.7M, down from $135.7M at 12/31/23.

No details on when a phase-2 COVID trial, with support from NIH, will start. The PR merely says, “phase-2 enabling activities…are underway.”

No CC.

👍️0

BurgerKing82 2年前

Is March 7 a significant catalyst to get in by?

👍️0

TheFinalCD 3年前

$ALGS PHASE 1 NEWS https://finviz.com/quote.ashx?t=ALGS&ty=c&ta=1&p=d

https://dilutiontracker.com/app/search/ALGS?a=dbb88c

👍️0

DewDiligence 3年前

ALGS 3Q23 results:

https://finance.yahoo.com/news/aligos-therapeutics-reports-recent-business-200500015.html

No CC.

👍️0

DewDiligence 3年前

ALGS -15% on warrant-laden $92M financing:

https://www.globenewswire.com/news-release/2023/10/23/2764690/0/en/Aligos-Therapeutics-Announces-92-Million-Private-Placement-Financing.html

👍️0

DewDiligence 3年前

ALGS receives $8.5M NIAID grant for clinical development of ALG-097558:

https://finance.yahoo.com/news/aligos-therapeutics-announces-award-8-113000446.html

$8.5M won’t go very far, but I suppose that every little bit helps. ALGS is expected to report data from the phase-1 trial of ALG-097558 in 1H24.

ALG-055009 phase-2a in NASH expected_to_start 1Q24:

https://finance.yahoo.com/news/aligos-therapeutics-announces-ind-clearance-113000003.html

ALG-055009 is a thyroid hormone receptor beta agonist.

ALGS, JNJ reach agreement in principle to settle pending litigation:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001799448/000119312523200617/d538755d8k.htm

The terms will presumably be disclosed when the settlement in finalized.

👍️0

DewDiligence 3年前

The relatively low cash burn in 2Q23 was due to ALGS’ slashing R&D expenses by more than half relative to 2Q22 ($17M in 2Q23 vs 2Q22 $35M).

👍️0

DewDiligence 3年前

ALGS 2Q23 results—6/30/23 cash=$91M—(down $15M from 3/31/23):

https://finance.yahoo.com/news/aligos-therapeutics-reports-recent-business-200500975.html

Data from the phase-1 trial of ALG-097558, a SARS-CoV-2 protease inhibitor, are expected in 1H24. The trial, which is being conducted in the UK, is currently in the SAD phase.

No CC.

👍️0

DewDiligence 3年前

ALGS HBV data at EASL:

https://www.globenewswire.com/news-release/2023/06/21/2692513/0/en/Aligos-Therapeutics-Presents-Data-from-its-Liver-Disease-Programs-at-the-European-Association-for-the-Study-of-the-Liver-EASL-Congress-2023.html

👍️0

DewDiligence 3年前

ALGS +51%/AH on collaboration with Chinese company:

https://finance.yahoo.com/news/aligos-therapeutics-announces-research-collaboration-210500298.html Under the terms of the agreement, Aligos and Amoytop* will collaborate on the research and development of oligonucleotide compounds for the treatment of liver diseases. Amoytop will receive an option to obtain an exclusive license to develop and commercialize the resultant products in the Greater China territory while Aligos will retain rest-of-world rights. Aligos will also receive an upfront payment and research collaboration funding and be eligible to receive up to a total of $109 million in development and sales milestone payments for licensed products as well as tiered royalties on net sales. Before the AH pop, ALGS’ enterprise value was deeply negative; after the AH pop, the EV is still negative but less so.

The up-front cash amount is presumably tiny since it wasn’t disclosed.

*Xiamen Amoytop Biotech Company Ltd.

👍️0

DewDiligence 3年前

ALGS 1Q23 results—3/31/22 cash=$104M, down from $126M at 12/31/22:

https://finance.yahoo.com/news/aligos-therapeutics-reports-recent-business-200500905.html

ALGS expects to start a phase-1 trial of ALG-097558, a SARS-CoV-2 protease inhibitor, in the UK in mid 2023.

No CC.

👍️0

DewDiligence 3年前

ALGS 4Q22 results—12/31/22 cash=$126M—4Q22 cash_burn=$16M:

https://finance.yahoo.com/news/aligos-therapeutics-reports-recent-business-210500130.html

ALGS’ COVID protease inhibitor, ALG-097558, is expected to start phase-1 in 2Q23.

No CC.

👍️0

DewDiligence 3年前

ALGS “de-prioritizes” HBV program—reduces workforce 10%:

https://finance.yahoo.com/news/aligos-therapeutics-announces-strategic-reprioritization-210500405.html Aligos Therapeutics…today announced a portfolio reprioritization. Aligos’ highest priorities will be focused on rapid advancement of its clinical NASH (ALG-055009) and COVID-19 (ALG-097558) programs as well as maintaining its ongoing NASH oligonucleotide research collaborations with Merck…

Additionally, the Company plans to complete the <=48-week (ALG-000184) and single ascending dose (ALG-125755) cohorts for its two chronic hepatitis B programs and continue to invest in selected research programs and collaborations with external research organizations.

This portfolio reprioritization is being accompanied by a reduction of the Company’s current workforce of approximately 10%...

…As a result of the portfolio reprioritization, realignment of its workforce, and other cost-saving measures, the Company expects to maintain a strong balance sheet and extend its projected cash runway to the end of 2024. In other words, the HBV program is getting the axe. After completing the early-stage HBV trials in progress, ALGS will offload these assets (if anyone wants them) or simply shut down the program.

The stock is flattish in the AH session.

👍️0

Laster 3年前

Might hit $3 today.
Easily moving to $5.
Discussed this on HEPA board at under $1 in December.
Wow.
Yippee.

👍️0

Laster 3年前

Beautiful. Will pass $2 today.
Best NASH play out there.
Good luck.

👍️0

Laster 3年前

It’s running.
Amazing NASH stock.
$1.20.
$3 in February.

👍️0

DewDiligence 3年前

ALGS provides 2023 roadmap:

https://www.globenewswire.com/news-release/2023/01/05/2583624/0/en/Aligos-Therapeutics-on-Track-to-Complete-Phase-2-Enabling-Activities-in-2023-for-its-Clinically-Validated-THR-%C3%9F-Drug-Candidate-for-NASH-ALG-055009.html

👍️0

DewDiligence 4年前

ALGS 3Q22 results—9/30/22 cash=$142M—3Q22 cash_burn=$17M:

https://www.globenewswire.com/news-release/2022/11/02/2547039/0/en/Aligos-Therapeutics-Reports-Recent-Business-Progress-and-Third-Quarter-2022-Financial-Results.html

ALGS’ COVID protease inhibitor, ALG-097558 is expected to start phase-1 in 2Q23.

No CC.

👍️0

DewDiligence 4年前

ALGS 2Q22 results—6/30/22 cash=$159.3M—(down from $183M @3/31/22):

https://www.globenewswire.com/news-release/2022/08/04/2492772/0/en/Aligos-Therapeutics-Reports-Recent-Business-Progress-and-Second-Quarter-2022-Financial-Results.html

Phase-1 for the SARS-CoV-2 protease inhibitor, ALG-097558 has been delayed and is now expected to start in 2023, following a CTA filing in 1Q23. (The prior guidance was for an IND filing in 2H22.)

👍️0

DewDiligence 4年前

ALGS—Cash @3/31/22=$183M—$23B burn in 1Q22:

https://finance.yahoo.com/news/aligos-therapeutics-reports-recent-business-200500766.html

Other than the financials, there is no new news. ALGS still plans to start phase-1 for its COVID protease inhibitor in late 2022 or early 2023 (i.e. IND filing in 2H22).

No CC.

👍️0

DewDiligence 4年前

ALGS selects lead SARS-CoV-2 PI—phase-1 expected to start in early 2023 (or very late 2022):

https://finance.yahoo.com/news/aligos-therapeutics-selects-drug-candidate-120000412.html

The timing of this program was known from the Leerink webcast two months ago (#msg-167924816), so the only new news is that a lead compound has been selected.

👍️0

DewDiligence 4年前

ALGS discontinues another HBV candidate:

https://finance.yahoo.com/news/aligos-discontinues-development-antisense-oligonucleotide-120000830.html Aligos Therapeutics…today announced that it has discontinued development of its drug candidate, ALG-020572, which was being studied in subjects with chronic hepatitis B (CHB).

Dosing in the first CHB cohort of Study ALG-020572-401 (NCT05001022) was stopped after one subject experienced a serious adverse event (SAE) with significant increase in alanine aminotransferase (ALT) following multiple dosing of 210 mg ALG-020572 that resulted in a brief hospitalization. This is one of four CHB subjects in this first cohort who experienced potentially drug-related ALT flares…

👍️0

DewDiligence 4年前

ALGS 4Q21 financials—12/31/21_cash=$205.8M:

https://finance.yahoo.com/news/aligos-therapeutics-reports-fourth-quarter-210500703.html

No CC.

👍️0

DewDiligence 4年前

Disclosure: I'm long ENTA.

👍️0

DewDiligence 4年前

Two takeaways from today's Leerink webcast on ALGS-9711 (oral coronavirus protease inhibitor): 1) ALGS-097111 phase-1 won’t start until 2023 (insofar as the IND is expected to be filed in late 2022); 2) CEO Blatt talked up combination therapy to treat COVID even while insisting compound is “best in class,” which I find curious.

👍️0

DewDiligence 4年前

Preclinical data on ALGS-097111 protease inhibitor from 2021 CROI:

https://www.aligos.com/wp-content/uploads/2021/03/CROI21_Science-Spotlight_ID2675_Vandyck_handout_1.pdf

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Aligos Therapeutics Inc (ALGS)

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

Aligos Therapeutics Inc (ALGS) ニュース

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Aligos Therapeutics Presents Positive Data at the EASL Congress 2026

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

Form 8-K - Current report

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Form 8-K - Current report

Aligos Therapeutics Jumps on China Licensing Agreement

Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

ALGS Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Aligos Therapeutics Inc (ALGS)

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

Aligos Therapeutics Inc (ALGS) ニュース

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Aligos Therapeutics Presents Positive Data at the EASL Congress 2026

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

Form 8-K - Current report

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Form 8-K - Current report

Aligos Therapeutics Jumps on China Licensing Agreement

Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

ALGS Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

ADVFNに参加する理由

プロトレーダー向けの高機能ツール

広告を削除する